Hello,
I just received a copy of my first MRI results, and I will be meeting with my Urologist in a few days to go over it. I was hoping for some clarity on what it means. My bio has the latest info of my PC journey and is listed below, thanks everyone for your support!
Quick Bio:
Sept 01, 2022: PSA 9.0
Sept 27, 2022: PSA 9.2
Oct 11, 2022: 12 core biopsy - Gleason 3+3, 3+4, 3+4 cancer found on 3 cores (G7 favorable grade 2).
Oct 15, 2022: Major lifestyle change
Nov 22 2022: PSA 7.9
Dec 23, 2022: PSA 6.8
Jan 19, 2023: PSA 6.0
Jan 23, 2023: MRI
Jan 23, 2023 MRI Report from UCLA:
Preliminary Result
3T MRI OF THE PROSTATE WITH AND WITHOUT CONTRAST
and with 3D post-processing
TECHNIQUE: MRI of the pelvis was performed on a 3 Tesla
Siemens Skyra scanner. A transabdominal phased array was
used. Small field of view sagittal, axial oblique and coronal
oblique T2W TSE high resolution images and diffusion weighted images with
apparent diffusion coefficient map were obtained. Pre- and postcontrast
axial dynamic view-sharing time-resolved gradient
recalled echo T1-weighted images are acquired with intravenous
administration of gadolinium contrast. Offline post-processing on a
dedicated InVivo DynaCAD 3 workstation was performed for
generation of time-intensity curves and pharmacokinetic maps
and 3D contouring of the prostate gland and any target lesions
using combined automated and manual segmentation techniques.
CONTRAST: gadobutrol (Gadavist) 1 mmol/mL inj 7.5 mL
GLUCAGON: No
COMPARISON: No prior MRI prostate available for comparison at the time of dictation.
CLINICAL HISTORY: prostate cancer
PSA (ng/mL): 9.2 on 9/2022
BIOPSY: Gleason 3+4=7 adenocarcinoma in 2 cores on
10/11/2022 with Genesis Healthcare Partners in OC
FINDINGS:
Quality: Excellent
The prostate measures 32 g based on contour, (4.5 cm x 3.3 cm x 3.9 cm).
PSA Density 0.29 ng/mL/cc.
The background transition zone is heterogeneous.
The background peripheral zone is heterogeneous. Linear and wedge-shaped T2 hypointensities throughout the peripheral zone (worse on the left) likely represent prostatitis or sequela
thereof.
Additional T1 hyperintense probable postbiopsy blood products at the left peripheral apical mid gland.
No suspicious findings for intermediate or high-grade neoplasia.
Limited views of the pelvis reveal no enlarged lymph nodes.
No focal bone lesions.
IMPRESSION:
No suspicious findings for intermediate or high-grade neoplasia.
Overall PI-RADS Category: 2/5
Standardized reporting guidelines follow recommendations by ACR-ESUR PI-RADS v2.1
THIS IS A PRELIMINARY REPORT THAT HAS NOT BEEN
REVIEWED BY AN ATTENDING RADIOLOGIST.
*Modified PI-RADSv2.1 Scoring for Dynamic Contrast-Enhanced
Imaging is utilized at UCLA as follows: a peripheral zone lesion
will only be considered positive if it corresponds to a focal
abnormality on T2-weighted and diffusion-weighted imaging and
enhances earlier than (not contemporaneously with) surrounding normal peripheral zone tissue.
Appendix (based on UCLA data/publications)
Overall MRI sensitivity for prostate cancer detection = 47%
Sensitivity for tumors > 1 cm or for Gleason > 3 + 4 = 72%
In-Bore MR-Guided Biopsy
PI-RADS 2: 7% PI-RADS 1/2: 15%
PI-RADS 3: 44% PI-RADS 3: 23%
PI-RADS 4: 63% PI-RADS 4: 64%
PI-RADS 5: 94% PI-RADS 5: 80%
CDR MR/US Fusion Biopsy CDR
1. Eur Urol 2019;75(5):712-720
2. Radiology 2017;283(1):130-139
3. Cancer 2016;122(6):884-892
4. Abdom Radiol 2016;41:954-962
5. Eur Urol 2015;67(3):569-576
6. Am J Roentgenol 2015;1:W87-92
Dictated by: (redacted) 1/23/2023 6:27 PM